Trevi Therapeutics’ (TRVI) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a $21.00 target price on the stock. HC Wainwright also issued estimates for Trevi Therapeutics’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at $0.70 EPS.

Several other equities analysts have also commented on TRVI. Needham & Company LLC dropped their target price on Trevi Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday. Morgan Stanley decreased their price objective on shares of Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. D. Boral Capital restated a “buy” rating and issued a $19.00 price objective on shares of Trevi Therapeutics in a research note on Friday, April 17th. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $22.90.

Trevi Therapeutics Price Performance

NASDAQ:TRVI opened at $14.50 on Wednesday. The firm has a market capitalization of $2.06 billion, a PE ratio of -45.31 and a beta of 1.07. The business’s fifty day moving average price is $12.69 and its 200 day moving average price is $11.95. Trevi Therapeutics has a 12 month low of $5.38 and a 12 month high of $16.12.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). As a group, equities analysts anticipate that Trevi Therapeutics will post -0.44 EPS for the current year.

Hedge Funds Weigh In On Trevi Therapeutics

Several large investors have recently bought and sold shares of TRVI. Alliancebernstein L.P. boosted its stake in Trevi Therapeutics by 19,064.5% in the second quarter. Alliancebernstein L.P. now owns 4,281,355 shares of the company’s stock valued at $23,419,000 after acquiring an additional 4,259,015 shares in the last quarter. Rubric Capital Management LP boosted its stake in shares of Trevi Therapeutics by 88.0% during the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after buying an additional 3,993,325 shares during the period. Viking Global Investors LP boosted its stake in shares of Trevi Therapeutics by 232.4% during the third quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock worth $46,929,000 after buying an additional 3,585,875 shares during the period. Wellington Management Group LLP boosted its stake in shares of Trevi Therapeutics by 1,792.0% during the third quarter. Wellington Management Group LLP now owns 3,253,888 shares of the company’s stock worth $29,773,000 after buying an additional 3,081,906 shares during the period. Finally, Marshall Wace LLP boosted its stake in shares of Trevi Therapeutics by 95.4% during the third quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock worth $44,302,000 after buying an additional 2,363,835 shares during the period. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trending Headlines about Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: HC Wainwright lifted near-term EPS estimates for Q2 2026 to ($0.11) from ($0.12), suggesting modestly better expected profitability. Trevi Therapeutics Q1 2026 Earnings Call Transcript
• Positive Sentiment: The firm also increased its Q3 2026 EPS estimate to ($0.14) from ($0.17), Q4 2026 to ($0.15) from ($0.17), and FY2026 to ($0.47) from ($0.54).
• Positive Sentiment: HC Wainwright kept a bullish long-term view, raising its FY2027 estimate to ($0.57) from ($0.63) and FY2028 to ($0.63) from ($0.66), while maintaining the same $21 price target.
• Neutral Sentiment: The analyst trimmed its FY2029 estimate to $0.70 from $0.79 in one report, but the overall tone remained constructive.
• Neutral Sentiment: Trevi recently reported a Q1 loss of ($0.09) per share, slightly wider than expectations, so the stock’s move appears driven more by improved forward estimates and analyst confidence than by the latest earnings print.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.